Essential oil may reduce PMS symptoms
NEW YORK — A new study published in BioMed Central’s open-access journal, Reproductive Health, found that essential fatty acids may reduce premenstrual syndrome symptoms among women.
In a randomized, controlled trial of 120 women, Edilberto Rocha Filho worked with a team of researchers from the Federal University of Pernambuco, Brazil, administered 1 or 2 grams of essential oil. Women who were given capsules containing 2 grams of a combination of gamma linolenic acid, oleic acid, linoleic acid, other polyunsaturated acids and vitamin E reported significantly eased PMS symptoms at both three and six months after they began the treatment.
"The negative effect of PMS on a woman’s routine activities and quality of life may be significant, in addition to the repercussions on economic costs resulting predominantly from a reduction in productivity. Essential oil capsules can now be said to show much promise as a treatment," the researchers noted, adding that "the administration of the dietary supplement did not result in any changes in the total cholesterol in the patients evaluated."
B. Braun’s wound management gel available for OTC use
BETHLEHEM, Pa. — B. Braun has launched its Prontosan wound management gel — a product used in the healthcare setting for cleaning wounds, as well as moistening and lubricating absorbent wound dressings — for over-the-counter use.
The ready-to-use gel contains PHMB and betaine, the surfactant for the cleansing and moistening of wounds. Its nontoxic and biocompatible formula also offers excellent skin tolerance, the company said.
"Effective wound care management no longer needs to be limited to within healthcare facility walls," said Mike Kelly, director of marketing, infection control products for B. Braun. "The 510(k) clearance [which occurred in November 2010] for OTC use of Prontosan wound management gel advances B. Braun’s commitment to infection prevention, helping to provide solutions that positively impact patients’ care in a physician’s office, acute care setting or in a patient’s home."
Pernix, ParaPro to promote prescription pediculicide if approved
MAGNOLIA, Texas — Pernix Therapeutics Holdings on Wednesday announced an exclusive co-promotion agreement with ParaPro for a medication to treat head lice.
A new drug application for the prescription product currently is under review by the Food and Drug Administration. The proposed medication contains the active ingredient spinosad, which is derived from a naturally occurring soil bacterium.
Under the terms of the agreement, if the drug containing spinosad is approved by the FDA, Pernix and ParaPro exclusively will co-promote the medication with a combined sales force in the United States. Pernix would leverage its established pediatric sales force to promote the drug to healthcare professionals who treat human head lice.
If approved, the product is expected to be available in the first half of 2011.